In her latest On target column, published by ESMO’s Daily Reporter, VHIO’s Elena Garralda reflects on the myriad research advances presented at last month’s ESMO Congress 2023, and how the conference superbly represented the strong foundations for next-generation precision oncology in a multitude of cancer types and disease settings.
As she considers the current state of precision oncology, she highlights the results of a study led by colleagues at the Memorial Sloan Kettering Cancer Center, New York, which published in Cancer Discovery* shortly before the meeting.
The study authors conducted a systematic assessment of how this field has grown and the extent to which its expansion has improved outcomes in cancer patients. Summarizing the main findings of this study, Elena briefly discusses the suggested directions which could move the field further forward.
She also focuses on equal access to, and affordability of, new anti-cancer medicines, as well as other aspects that need to be addressed, prepared for, and solved. Illustrative of these efforts at ESMO Congress this year, was the announcement of the ESMO Public Policy Manifesto on key issues for oncology, to be published early 2024.
To discover more, we invite you to read Elena’s latest column here. To browse all previous editions of On target please click here.
Elena Garralda is Executive Director of VHIO’s Research Unit for Molecular Therapy of Cancer (UITM) – CaixaResearch, Principal Investigator of our Early Clinical Drug Development Group, and co-Director of VHIO’s Clinical Research Program.
—-
*Suehnholz SP, Nissan MH, Zhang H, Kundra R, Nandakumar S, Lu C, Carrero S, Dhaneshwar A, Fernandez N, Xu BW, Arcila ME, Zehir A, Syed A, Brannon AR, Rudolph JE, Paraiso E, Sabbatini PJ, Levine RL, Dogan A, Gao J, Ladanyi M, Drilon A, Berger MF, Solit DB, Schultz N, Chakravarty D. Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer. Cancer Discov. 2023 Oct 18. doi: 10.1158/2159-8290.CD-23-0467. Epub ahead of print. PMID: 37849038.
